@article{8a98849b16a74fd3a8010bc937278593,
title = "Clinically Relevant Changes in Emotional Expression in Children With ADHD Treated With Lisdexamfetamine Dimesylate",
abstract = "Objective: To describe clinically relevant effects of lisdexamfetamine dimesylate (LDX) on emotional expression (EE) in children with ADHD. Method: Children with ADHD participated in a 7-week, open-label, LDX dose-optimization study. Expression and Emotion Scale for Children (EESC) change scores were analyzed post hoc using two methods to determine proportion of participants with different categories of clinical response based on (a) clinically significant (movement >2 SD from baseline mean)/reliable change (not due to measurement error) and (b) standard error of measurement (SEM) as a measure of clinically meaningful change. Results: With LDX, no participants showed clinically significant/reliable improvement; 0.7% showed clinically significant/reliable deterioration of EE by reliable change index and movement from baseline mean. One third of participants had improved EE by SEM criteria; 9.2% had categorical worsening. Conclusion: Using clinically meaningful change and clinically significant/reliable change categories derived from the EESC, most participants had no worsening of EE with LDX.",
keywords = "ADHD, LDX, Lisdexamfetamine dimesylate, emotional lability, stimulant",
author = "Alain Katic and Lawrence Ginsberg and Rakesh Jain and Ben Adeyi and Bryan Dirks and Thomas Babcock and Brian Scheckner and Cynthia Richards and Robert Lasser and Atilla Turgay and Findling, {Robert L.}",
note = "Funding Information: Dr Turgay received research grant support or served as a consultant or speaker for AstraZeneca, Canadian Counseling Foundation, Canadian Independent Films Institute, Canadian Psychiatric Association, CellTech, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Janssen Ortho, Lundbeck, Hospital for Sick Children, Nestle, Novartis, Ontario Ministry of Children{\textquoteright}s Services, Ontario Psychiatric Association, Purdue Pharma, Sanofi-Aventis, Shire Canada, Shire UK, Shire US, The Scarborough Hospital, Turkish Medical Research Council, University of Ottawa, and Wellesley Foundation Canada. Funding Information: Dr Katic receives or has received research grant support from Abbott Laboratories, Alexza, AstraZeneca, Bristol-Myers Squibb, Cephalon, Corcept, Cyberonics, Dainippon Sumitomo, Eli Lilly, Forest, GlaxoSmithKline, Hisamitsu, Lundbeck, Merck, Novartis, Organon, Otsuka, Pfizer, Sanofi-Aventis, Sepracor, Shire, Takeda, and Wyeth; and served on a speaker{\textquoteright}s bureau for Novartis, Pfizer, and Shire. Funding Information: Dr Ginsberg receives or has received research grant support from Abbott Laboratories, Alkermes, AstraZeneca, Bristol-Myers Squibb, Cephalon, Cyberonics, Eli Lilly, Forest, GlaxoSmithKline, Janssen, McNeil, Neurocrine Biosciences, Neuropharm, New River, Novartis, Organon, Ortho-McNeil, Otsuka, Pam Labs, Pfizer, Sanofi-Aventis, Seaside Therapeutics, Sepracor, Shire, Takeda, UCB Pharma, Validus, and Wyeth; served on a speaker{\textquoteright}s bureau for Alkermes, AstraZeneca, Bristol-Myers Squibb, Cephalon, Cyberonics, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Jazz, JDS Pharmaceuticals, McNeil, Novartis, Noven, Organon, Pam Labs, Pfizer, Sanofi-Aventis, Schwarz, Sepracor, Shire, Takeda, UCB Pharma, Validus, and Wyeth; and is a consultant for AstraZeneca, Bristol-Myers Squibb, Cephalon, Cyberonics, Eli Lilly, Forest, GlaxoSmithKline, Janssen, McNeil, Novartis, Ortho-McNeil, Pfizer, Sanofi-Aventis, Sepracor, Shire, Takeda, UCB Pharma, Validus, and Wyeth. Funding Information: Clinical research was funded by the sponsor, Shire Development Inc. Under the direction of the authors, Margaret McLaughlin, PhD, former employee of Ogilvy CommonHealth Scientific Communications (OCHSC) and Michael Pucci, PhD, employee of OCHSC, provided writing assistance for this publication. Editorial assistance in formatting, proofreading, copy editing, and fact checking was also provided by OCHSC. Ben Adeyi, MS, Bryan Dirks, MD, Brian Scheckner, PharmD, Thomas Babcock, DO, from Shire Development Inc. also reviewed and edited the manuscript for scientific accuracy. Shire Development Inc. provided funding to OCHSC for support in writing and editing this manuscript. Although the sponsor was involved in the design, collection, analysis, interpretation, and fact checking of information, the content of this manuscript, the ultimate interpretation, and the decision to submit it for publication in Journal of Attention Disorders were made by the authors independently.",
year = "2012",
month = jul,
doi = "10.1177/1087054710389990",
language = "English (US)",
volume = "16",
pages = "384--397",
journal = "Journal of Attention Disorders",
issn = "1087-0547",
publisher = "SAGE Publications Inc.",
number = "5",
}